These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 11436152)

  • 1. Mesothelioma: diagnostic immunohistochemical markers.
    Chilosi M
    Adv Clin Path; 2000 Oct; 4(4):179-83. PubMed ID: 11436152
    [No Abstract]   [Full Text] [Related]  

  • 2. Epithelioid lesions of the serosa.
    Anttila S
    Arch Pathol Lab Med; 2012 Mar; 136(3):241-52. PubMed ID: 22372900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The diagnostic utility of p16 FISH and GLUT-1 immunohistochemical analysis in mesothelial proliferations.
    Monaco SE; Shuai Y; Bansal M; Krasinskas AM; Dacic S
    Am J Clin Pathol; 2011 Apr; 135(4):619-27. PubMed ID: 21411785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of immunohistochemistry in the differential diagnosis of serous effusions.
    Cangi MG; Pecciarini L; Doglioni C
    Adv Clin Path; 2000 Oct; 4(4):183-5. PubMed ID: 11436153
    [No Abstract]   [Full Text] [Related]  

  • 5. Novel marker D2-40, combined with calretinin, CEA, and TTF-1: an optimal set of immunodiagnostic markers for pleural mesothelioma.
    Mimura T; Ito A; Sakuma T; Ohbayashi C; Yoshimura M; Tsubota N; Okita Y; Okada M
    Cancer; 2007 Mar; 109(5):933-8. PubMed ID: 17279584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value of immunohistochemistry in the differential diagnosis of pleural sarcomatoid mesothelioma from lung sarcomatoid carcinoma.
    Takeshima Y; Amatya VJ; Kushitani K; Kaneko M; Inai K
    Histopathology; 2009 May; 54(6):667-76. PubMed ID: 19438742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The importance of retaining post mortem tissue--'pseudomesotheliomatous' Merkel cell carcinoma of the pleura.
    Leopold GD; Attanoos RL
    Histopathology; 2011 Jun; 58(7):1180-2. PubMed ID: 21707722
    [No Abstract]   [Full Text] [Related]  

  • 8. Biomarkers for mesothelioma.
    Scherpereel A; Lee YC
    Curr Opin Pulm Med; 2007 Jul; 13(4):339-443. PubMed ID: 17534183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pleural mesothelioma presenting initially as empyema.
    Smith R; Nguyen GK
    Diagn Cytopathol; 2003 Aug; 29(2):119-21. PubMed ID: 12889054
    [No Abstract]   [Full Text] [Related]  

  • 10. Claudin-4 in mesothelioma diagnosis.
    Facchetti F; Gentili F; Lonardi S; Bercich L; Santin A
    Histopathology; 2007 Aug; 51(2):261-3. PubMed ID: 17573941
    [No Abstract]   [Full Text] [Related]  

  • 11. [Detection of p16 by fluorescence in-situ hybridization and immunohistochemistry in malignant mesothelioma].
    Liu Y; Chen X; Ding N; Xu W; Yang H; Chen X
    Zhonghua Bing Li Xue Za Zhi; 2015 Apr; 44(4):262-5. PubMed ID: 25975910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Applications and limitations of immunohistochemistry in the diagnosis of malignant mesothelioma.
    Suster S; Moran CA
    Adv Anat Pathol; 2006 Nov; 13(6):316-29. PubMed ID: 17075297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness of EMA, GLUT-1, and XIAP for the cytologic diagnosis of malignant mesothelioma in body cavity fluids.
    Shen J; Pinkus GS; Deshpande V; Cibas ES
    Am J Clin Pathol; 2009 Apr; 131(4):516-23. PubMed ID: 19289587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathology of malignant mesothelioma.
    Van Marck E
    Lung Cancer; 2004 Aug; 45 Suppl 1():S35-6. PubMed ID: 15261431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The diagnostic utility of D2-40 for malignant mesothelioma versus pulmonary carcinoma with pleural involvement.
    Saad RS; Lindner JL; Lin X; Liu YL; Silverman JF
    Diagn Cytopathol; 2006 Dec; 34(12):801-6. PubMed ID: 17115439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Biochemical diagnosis of pleural epithelioma].
    Havez R; Tacquet A; Biserte G; Foissac-Gégoux P; Degand P; Lelièvre G; Gosselin B; Duthoit A
    Lille Med; 1967 Apr; 12(4):460-6. PubMed ID: 5619108
    [No Abstract]   [Full Text] [Related]  

  • 17. Validation of tissue microarray technology in malignant pleural mesothelioma.
    Kao SC; Lee K; Armstrong NJ; Clarke S; Vardy J; van Zandwijk N; Reid G; Burn J; McCaughan BC; Henderson DW; Klebe S
    Pathology; 2011 Feb; 43(2):128-32. PubMed ID: 21233673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mesothelioma versus carcinoma: getting easier?
    Battifora H
    Hum Pathol; 2005 Nov; 36(11):1153. PubMed ID: 16260266
    [No Abstract]   [Full Text] [Related]  

  • 19. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
    Friedman MT; Gentile P; Tarectecan A; Fuchs A
    Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The high post-test probability of a cytological examination renders further investigations to establish a diagnosis of epithelial malignant pleural mesothelioma redundant.
    Aerts JG; Delahaye M; van der Kwast TH; Davidson B; Hoogsteden HC; van Meerbeeck JP
    Diagn Cytopathol; 2006 Aug; 34(8):523-7. PubMed ID: 16850492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.